Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial-Reference-Cited by-同舟云学术

Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial

Published:2012-05 Issue:5 Volume:13 Page:528-538
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Miller Vincent A,Hirsh Vera,Cadranel Jacques,Chen Yuh-Min,Park Keunchil,Kim Sang-We,Zhou Caicun,Su Wu-Chou,Wang Mengzhao,Sun Yan,Heo Dae Seog,Crino Lucio,Tan Eng-Huat,Chao Tsu-Yi,Shahidi Mehdi,Cong Xiuyu Julie,Lorence Robert M,Yang James Chih-Hsin

Publisher

Elsevier BV

Subject

Oncology

Reference31 articles.

1. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions;Pao;J Clin Oncol,2005

2. An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor;Kobayashi;Cancer Res,2005

3. Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation;Oxnard;Clin Cancer Res,2011

4. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models;Li;Oncogene,2008

5. Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors;Yap;J Clin Oncol,2010

Cited by 866 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment Advances in Lung Cancer with Leptomeningeal Metastasis;Current Cancer Drug Targets;2024-09

2. Immune killer cells treatment for previously treated stage IV NSCLC patients;Scientific Reports;2024-08-21

3. Targeting of drug-tolerant persister cells as an approach to counter drug resistance in non-small cell lung cancer;Lung Cancer;2024-08

4. Nephrotoxicity of targeted therapy used to treat lung cancer;Frontiers in Immunology;2024-07-04

5. New-onset keratitis associated with epidermal growth factor receptor-based targeted therapies in Han Chinese patients with lung cancer: A multi-center cohort study;The Ocular Surface;2024-07